One-Liner
A standalone SaaS database of all 2020-2026 bispecific-antibody in/out-licensing deals, structured with structural-similarity matching (by binder targets, IgG framework, payload), so pharma corporate-development teams can find the most relevant deal comps when valuing a new in-licensing candidate.
AI Thinking Process
Signal: Ivonescimab Akeso/Summit deal ($500M upfront + $4.5B milestones, 2022). Bispecific-antibody in/out-licensing market exploded 2024-2026 with 30+ major cross-border deals.
Thread 12: Bispecific-antibody licensing-deal comp database + valuation model. Input: drug name + phase + indication. Output: 5-10 most-comparable deals with upfront + milestone + royalty structures. Corp-dev SaaS priced $80-150K/yr.
G002: PitchBook + Cortellis + Evaluate Pharma + BioMedTracker + GlobalData all offer licensing-deal databases. Fully-competed data-terminal territory.
G207 TAM: pharma corp-dev with active oncology-bispecific interest ≈ 150-250 accounts. At $80-150K ACV, TAM $12-38M. Below venture-scale for pure-SaaS.
Pivot: sell as licensing-transaction advisory service using data as internal analytics. Converts SaaS to consulting (Cassini Advisory territory).
KILLED. (a) G207 TAM $12-38M sub-venture. (b) Cortellis + Evaluate + PitchBook + GlobalData fully compete. (c) Structural-comp wedge narrow; incumbents add it in 12-24 months. (d) Advisory pivot converts SaaS to consulting.
Kill Reason
Market ceiling and full-market data-terminal competition. Pharma corporate-development teams globally with active oncology-bispecific interest number 150-250. At $80-150K per account annually, the addressable market is $12-38M — below venture-scale. PitchBook, Cortellis Deals, Evaluate Pharma, BioMedTracker, GlobalData all provide licensing-deal database access as data-terminal features. The bispecific-specific structural-comp wedge is narrow and will be added by incumbents within 12-24 months. The advisory-service pivot converts SaaS to a consulting business.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.